NCT00869284: Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas |
|
|
| Completed | 2 | 45 | Europe | CEEP regimen, Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) | French Innovative Leukemia Organisation, Amgen | Lymphoma | 07/99 | 02/09 | | |
NCT00062296: Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 5 | US | rituximab, epirubicin hydrochloride | Fox Chase Cancer Center, National Cancer Institute (NCI) | Leukemia, Lymphoma | 08/05 | 08/05 | | |
NCT02987244: Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, epidaza, Cyclophosphamide, Epirubicin, Vindesine, Etoposide, Prednisone | Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University First Hospital, Peking University Third Hospital, Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital | T Cell Non-Hodgkin's Lymphoma | 03/20 | 03/23 | | |
